8-K/A: Geron Corporation Announces CEO Transition: John Scarlett Resigns, Dawn Bir Appointed Interim CEO

Geron Corporation announces the resignation of John A. Scarlett as CEO and the appointment of Dawn C. Bir as Interim CEO, effective March 10, 2025.

Summary

• John A. Scarlett, M.D., concluded his service as President, CEO, and Chairman of Geron Corporation on March 10, 2025, and resigned from the Board.
• Dr. Scarlett will remain employed by the company through March 31, 2025, to assist with the transition.
• Dawn C. Bir, a current member of the Board, has been appointed as Interim President and CEO while the company searches for a permanent replacement.
• Ms. Bir has served as a director of Geron since March 2019 and has extensive experience in the biopharmaceutical industry.
• Elizabeth G. OFarrell, currently the Lead Independent Director, has been appointed Chair of the Board, effective March 10, 2025.
• Ms. Bir's compensation as Interim President and CEO includes an annualized base salary of $750,000 and an option to purchase 180,000 shares of Geron common stock.
• The option award will vest on the earlier of the first anniversary of the grant date (the date of the Company's 2025 Annual Meeting of Stockholders) or the next annual meeting following the grant date, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there's a leadership change, an experienced interim CEO has been appointed, and the company is actively seeking a permanent replacement. The financial details of the interim CEO's compensation are also provided.

Positives

• Dawn Bir brings extensive experience in the biopharmaceutical industry to the role of Interim CEO.
• The company is actively searching for a permanent CEO, indicating a commitment to long-term leadership.
• Elizabeth G. OFarrell's appointment as Chair of the Board provides continuity and leadership.

Negatives

• The departure of the CEO creates uncertainty in leadership.
• Dawn Bir is not eligible for the company's incentive bonus program or severance plan in her interim role.

Risks

• The search for a permanent CEO could be lengthy and disruptive.
• The transition in leadership could impact the company's strategic direction and operations.
• Uncertainty surrounding the permanent CEO position could affect investor confidence.

Future Outlook

The company is conducting a search for a permanent Chief Executive Officer.

Industry Context

Leadership transitions are common in the biopharmaceutical industry, especially for companies in clinical development stages. Interim appointments provide stability while a thorough search for a permanent leader is conducted.

Comparison to Industry Standards

• Interim CEO compensation packages often include a base salary and equity awards to incentivize performance during the transition period.
• The size of the option award granted to Dawn Bir is within the typical range for interim executive compensation in the biopharmaceutical industry, but will depend on the size of the company and the stage of development of their lead drug.
• Comparable companies such as Soleno Therapeutics, Inc. where Dawn Bir is also a board member, may offer similar compensation structures for interim executives.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the leadership transition.
• Employees may be affected by changes in strategic direction under new leadership.
• Customers and partners may experience minimal impact as the company continues operations under interim leadership.

Next Steps

• The company will continue its search for a permanent Chief Executive Officer.
• Dawn Bir will serve as Interim President and CEO while the search is conducted.
• The Option Award will be granted to Ms. Bir on the date of the Company's 2025 Annual Meeting of Stockholders.

Key Dates